Advertisement

Topics

Companies Related to "A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies" [Most Relevant Company Matches] RSS

15:58 EST 21st November 2018 | BioPortfolio

Here are the most relevant search results for "A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies" found in our extensive corporate database of over 50,000 company records.

Showing "Study NKTR Combination With NKTR With NKTR Plus" Companies 1–25 of 662

Relevant

Nektar Therapeutics

We are a biopharmaceutical company with a different approach to medicine. We develop drugs that are easier to take, safer to use, longer lasting and more effective. We look closely at existing therapies, and leverage our knowledge and extensive development expertise to evaluate how they can more effectively impact patients’ lives. Just over 15 years ago, our company was founded on breakthrough...


Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Hanmi Pharmaceutical co., Ltd.

Hanmi Pharmaceutical is a Korea-based pharmaceutical company. The Company invests over 20 percent of its sales in R&D and has over 20 programs consisting of the novel long acting biologics including weekly Insulin, weekly to monthly GLP-1, and their combination for diabetes and obesity (collectively referred as Quantum Project), the novel targeted anti-can...


Carbylan BioSurgery, Inc.

Carbylan (www.carbylan.com) was founded in 2005 to develop and market medical devices and device/drug combination products based on novel chemically engineered polymer systems incorporating hyaluronic acid, a well-known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Cytheris SA

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transp...

i3 Statprobe

Because we're strong in every area, you can outsource an entire study to i3 Statprobe, or outsource, for example, only the statistical programming for a single study. Or you can outsource only the statistical programming for every study. Use us any way you want to, we encourage it. For example, we'll provide a dedicated team of specialists (say, data coordinators or statistical programmers) to wor...

Probably Relevant

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

PharmaLinkFHI, Inc.

PharmaLink provides complete eClinical research services to support and streamline the drug development process. Clinical teams leverage real-time study information to make immediate decisions based on emerging trends and study issues. Our accelerated processes, centralized information management and global reach make it possible to conduct trials of any size or complexity from virtually anywhere....

GlycoMark, Inc.

GlycoMark is an FDA-cleared blood test that reveals repeated episodes of postprandial hyperglycemia/glycemic variability by tracking postprandial glucose levels as they related to blood levels of the molecule 1,5-anhydroglucitol (1,5-AG). Multiple published studies indicate that 1,5-AG detects hyperglycemia not detected by the hemoglobin A1C test. A recent study conducted as part of the internat...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

KARD Scientific

KARD scientific is the reliable resource for all your in vivo efficacy studies in drug discovery and development. For high quality, efficiency and cost effective services in cancer, neurological, inflammation, arthritis and other disease models. We can assist you in study design and methods for screening. We optimize the schedule, time points, routes, and combination studies, while keeping cl...

PharmaTech Solutions Inc

PTS was founded in 1999 by a group of pharmaceutical research professionals who believed that a pioneering approach was required to solve the industry’s study enrollment problems. Through innovation and excellence, PTS has amassed the technology and experience to develop patient recruitment solutions that identify and address the core issues that can hinder enrollment. PTS understands that findi...

TABS Group, Inc.

The 2010 TABS Group Vitamin Study was conducted among 1,000 representative respondents aged 18-75 in the TNS panel. The responses were combined with TABS Group's proprietary modeling capabilities to derive the market size estimates for the Vitamin Category. The study was fielded in May 2010, and it replicated a study that was completed in January 2008. TABS Group is a leading provider of resear...

nTouch Research Corporation

nTouch Research Corporation is a leading provider of Phase II-IV clinical trials services delivering investigator selection, patient recruitment and study management services for pharmaceutical, CRO, and biotechnology industries.nTouch owns and operates 16 highly-rated research centers across the USA serving 250 private practice investigators. Our strength is our commitment to sponsors, investigat...

GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and ...

Vitrolife AB (publ)

The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been ...

Sg2

Sg2, a Vizient company, enables health care executives to make better, faster, more cost-effective strategic decisions through a unique combination of industry leading market analytics and unrivaled expertise. Visit Sg2.com for more information.

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

International Pharmaceutical Research Center

International Pharmaceutical Research Center the commitment to unparalleled Quality Research. Our strength is our recognition from sponsors, investigators, and study subjects in conducting each study with dedication and a personal touch, while maintaining strict compliance with good clinical practice.

&intoconnection

&intoconnection performed a study on what it means for people to be strongly or weakly connected. Due to the international nature of the study, it is not only possible to measure connection by country, but it is also possible to compare connection between countries. The 14 countries studied were China, Japan, the U.S., Russia, Germany, Great Britain, France, Spain, South Africa, Argentina, Isr...


More From BioPortfolio on "A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks